RESEARCH ARTICLE
Effects of Eprosartan on Serum Metabolic Parameters in Patients with Essential Hypertension
Evangelos C. Rizos1, Athanasia Spyrou1, Evangelos N. Liberopoulos1, Eleni C. Papavasiliou2, Vasilis Saougos1, Alexandros D. Tselepis2, Moses Elisaf1, *
Article Information
Identifiers and Pagination:
Year: 2007Volume: 1
First Page: 22
Last Page: 26
Publisher ID: TOCMJ-1-22
DOI: 10.2174/1874192400701010022
Article History:
Received Date: 26/9/2007Revision Received Date: 1/10/2007
Acceptance Date: 2/10/2007
Electronic publication date: 14/11/2007
Collection year: 2007

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
The effect of the anti-hypertensive drug eprosartan on metabolic parameters is currently not extensively documented. We evaluated the effect of eprosartan on parameters involved in atherogenesis, oxidative stress and clotting activity. This open-label unblinded intervention study included 40 adult patients with essential hypertension taking eprosartan. Eprosartan significantly reduced by 8% (p<0.001) the systolic and by 13% (p<.001) the diastolic blood pressure, and in-creased by 24% the time needed to produce oxidative by-products (p=0.001), a marker of oxidative stress. In contrast, ep-rosartan did not alter 8-isoprostane (8-epiPGF2a) levels, another marker of oxidative stress. Additionally, eprosartan re-duced by 14% aspartate aminotransferase and by 21% then alanine aminotransferase activity, while it had a neutral effect on the lipid profile and apolipoprotein levels and did not influence glucose homeostasis, creatinine and uric acid levels. Eprosartan did not affect the clotting/fibrinolytic status (estimated by plasminogen activator inhibitor 1, tissue plasmino-gen activator and a2 antiplasmin levels), or the enzymatic activity of the lipoprotein associated phospholipase A2 (Lp-PLA2) and paraoxonase 1 (PON1). In conclusion, eprosartan should be mainly considered as an anti-hypertensive agent with neutral effects on most of the metabolic parameters in hypertensive patients.